Back to Rankings
Tianjin Ringpu Bio-technology Co., Ltd.
Brand VerifiedChina

Tianjin Ringpu Bio-technology Co., Ltd.

Ringpu

Ringpu Biology (Tianjin Ringpu Bio-technology Co., Ltd.) is China's preeminent listed animal health manufacturer and the only Asian-headquartered company in this global Top 10 ranking. Founded in 1998 and headquartered in Tianjin, China, Ringpu generated CNY 3.398 billion (~USD 470 million) in 2025 revenue (up 7.72%), with its pet health segment surging 24.39% to CNY 858 million. Ringpu's defining

ChinaEst. 19981,000+CNY 3.398 billion (~USD 470 million, 2025)11 mega-scale production bases with 94 production linesSZSE: 300119Score 89

Business Nature

Ringpu Biology is China's preeminent listed animal health manufacturer, operating 11 mega-scale production bases housing 94 fully automated, high-compliance production lines with over 500 veterinary drug product approvals. The company's defining competitive advantage is its "API-to-formulation" vertical integration strategy—by controlling upstream active pharmaceutical ingredient synthesis and biological fermentation in-house, Ringpu is completely immune to upstream supply chain bottlenecks and can aggressively undercut competitor pricing.

Its pet health segment achieved CNY 858 million in 2025 revenue up 24.39% YoY, driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides. Most critically, Ringpu has built an unparalleled "manufacturing-to-endpoint" closed ecosystem in China: through its affiliate Zhongrui Supply Chain and sister company Ringpai Pet Hospital network, it directly serves over 14,000 veterinary endpoints nationwide—eliminating layers of distributors and maximizing factory utilization.

Core Business Areas

Animal Health Portfolio — Core Business
• Pet Vaccines: feline triple / canine quadrivalent
• Parasiticides: long-acting oral/topical formulations
• Anti-infectives & Anti-inflammatories
• Biologics: avian/swine vaccines
• Diagnostic Kits & Devices
• Feed Additives & Nutritional Supplements
• Disinfectants

Industry Rankings

Corporate Report

Ringpu Biology (Tianjin Ringpu Bio-technology Co., Ltd.) is a China-based listed animal health manufacturer headquartered in Tianjin. Founded in 1998, Ringpu has grown to become China's largest publicly-traded animal health company by manufacturing scale. In 2025, Ringpu generated CNY 3.398 billion (~USD 470 million) in revenue (up 7.72%), with its pet health segment achieving CNY 858 million (up 24.39%), operating 11 mega-scale production bases with 94 automated lines and over 500 product approvals.

Core Business

Ringpu's companion animal portfolio has become the company's primary growth engine, with feline triple vaccines, canine quadrivalent vaccines, and long-acting parasiticides driving 24.39% YoY pet segment growth. The company's "API-to-formulation" vertical integration—controlling upstream pharmaceutical ingredient synthesis and biological fermentation entirely in-house—enables aggressive pricing while maintaining healthy margins. Its 500+ product approvals span vaccines, anti-infectives, parasiticides, diagnostic kits, feed additives, and disinfectants.

Global Presence

While currently China-centric, Ringpu's manufacturing infrastructure is globally significant: 11 mega-scale production bases with 94 high-compliance automated lines represent the largest single-country animal health manufacturing footprint in Asia. The company's unique "manufacturing-to-endpoint" ecosystem—linking its factories through the Zhongrui Supply Chain to the Ringpai Pet Hospital network's 14,000+ veterinary endpoints—creates an unparalleled closed loop that eliminates distributor markups and maximizes factory utilization rates.

Key Strengths

• Largest animal health manufacturing footprint in China with 11 bases, 94 lines, and 500+ approvals
• Pet segment hypergrowth at 24.39% YoY to CNY 858 million in 2025
• API-to-endpoint closed ecosystem serving 14,000+ veterinary endpoints directly
• Vertical integration eliminating upstream supply chain dependencies
• Formidable regulatory barrier with 500+ domestic product approvals

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Tianjin, China

Founded

1998

Employees

1,000+

Factories

11 mega-scale production bases with 94 production lines

Listing

SZSE: 300119

Categories

Veterinary Pharmaceuticals & Pet Healthcare CompaniesVeterinary Pharmaceuticals & Pet Healthcare Manufacturers & SuppliersPharmaceutical Drug CompaniesPharmaceutical Drug Manufacturers & SuppliersBiological Products & Vaccines CompaniesBiological Products & Vaccines ManufacturersHome Medical Devices BrandsMedical Consumables & Diagnostic Reagents CompaniesMedical Consumables & Diagnostic Reagents Manufacturers & Suppliers

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SZSE: 300119 , Ringpu Official Website
Shenzhen Stock Exchange — Ringpu (300119)
Wikipedia — Ringpu Biology